Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Evkeeza for homozygous familial hypercholesterolemia

Feb. 12, 2021

European Commission approves Ogluo to treat severe hypoglycemia

Feb. 12, 2021

Data on HMI-203 from animal studies support its further development for treating MPS II

Feb. 12, 2021

Preclinical findings support the use of HMI-202 for treating MLD

Feb. 12, 2021

FDA clears IND for trial of LYS-GM101 in GM1 gangliosidosis

Feb. 12, 2021

Amicus reports topline phase III data on AT-GAA for late-onset Pompe disease

Feb. 12, 2021

OncoArendi Therapeutics discovers AMCase and CHIT1 inhibitors

Feb. 10, 2021

AVROBIO reports new advances with upgraded gene therapy platform

Feb. 9, 2021

Phase Ib data presented for DA-1241 patients with type 2 diabetes

Feb. 9, 2021

King Abdulaziz University describes DPP-IV inhibitors

Feb. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...